Clinical Trial Update: Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

View source ↗

Summary

A patient-reported outcome study (CM-PRO) is being conducted in a subset of AU-011-301 (CoMpass) trial participants, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Melanoma
• Ocular Melanoma
• Uveal Melanoma

Drugs mentioned

• AU-011 (Belzupacap Sarotalocan)

Snippet

Sponsor: Aura Biosciences | Conditions: Choroidal Melanoma, Indeterminate Lesions | Status: RECRUITING